Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is a biomarker study with the goal of measuring changes in proteins and gene
methylation. This study is not intended for use in diagnosing, mitigating, treating, curing,
or preventing disease.
The purpose of this study is to determine if Vitamin D (cholecalciferol) alone and in
combination with celecoxib (Celebrex, a non-steroidal anti-inflammatory drug, or NSAID), to
decrease breast cancer risk by their effect on certain biological indicators (biomarkers) of
breast cancer risk (called PGE2, COX-2, and 15-PGDH) and cell changes in the breast.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hartford Hospital
Collaborators:
United States Department of Defense University of North Dakota
Treatments:
Celecoxib Cholecalciferol Ergocalciferols Prostaglandin Antagonists Vitamin D Vitamins